

SCHEDULE - DETAILED VIEW

2022 ASCP Annual Meeting

SUNDAY, MAY 29

New Investigator Award (NIA) Meet and Greet (Invitation Only)

Sun 6 PM - 7 PM • Moor 1

MONDAY, MAY 30

NIA Workshop (Invitation Only)

Mon 8 AM - 4:55 PM • Palomino Ballroom 9-10

Registration

Mon 1 PM - 5 PM • Princess East Foyer Desk

Speaker Ready Room

Mon 1 PM - 5 PM • Bourbon 11

2020 & 2021 New Investigator Awardee Dinner (Invitation Only)

Mon 7 PM - 9 PM • Moor 1

TUESDAY, MAY 31

NIA Breakfast Roundtable (Invitation Only)

Tue 7:30 AM - 8:30 AM • Castile 1

Morning Break

Tue 7:30 AM - 9 AM • Princess East Foyer

Registration

Tue 7:30 AM - 6 PM • Princess East Foyer Desk

Speaker Ready Room

Tue 7:30 AM - 6 PM • Bourbon 11

Conference Opening

Tue 8:30 AM - 9 AM • Salon A-E

Panel Sessions

The panel in Princess Ballroom H: Biomarkers in Clinical Studies: Is the Juice Worth the Squeeze? is not available for CE credit.

Tue 9 AM - 10:30 AM

Biomarkers in Clinical Studies: Is the Juice Worth the Squeeze?

Tue 9 AM - 10:30 AM • Panel • Princess Ballroom H

William Potter, M.D., Ph.D. *Chair*

Foundation of the National Institutes of Health

9 AM - 9:05 AM

Larry Ereshefsky, BCPP, Pharm.D. *Co-Chair*

APEX Innovative Sciences

9:05 AM - 9:10 AM

Margaret Grabb, Ph.D. *Speaker*

National Institute of Mental Health

How Biomarkers Can Inform Trial Design or Trial Outcomes: A Program Officer's Perspective on Portfolio Need

9:10 AM - 9:30 AM

William Potter, M.D., Ph.D. *Speaker*

Foundation of the National Institutes of Health

The Potential of Neurogenetic Disorders with Neuropsychiatric Presentation to Improve the Juice Concentration for the Biomarker Squeeze

9:30 AM - 9:50 AM

Scott Hobson, Ph.D. *Speaker*

Boehringer Ingelheim Pharma GmbH & Co KG

Enabling Precision Psychiatry: Why Should biomarkers be Incorporated into CNS Drug Discovery from Pre-clinical Research to Clinical Application and What do they Deliver?

9:50 AM - 10:10 AM

Brett English, Ph.D., Pharm.D. *Discussant*

Apex Innovative Sciences

10:10 AM - 10:30 AM

*Improving Schizophrenia Treatment Outcome: New Data and New Strategies

Tue 9 AM - 10:30 AM • Panel • Princess Ballroom I

Ira Glick, M.D. *Chair*

Stanford University School of Medicine

9 AM - 9:10 AM

John Davis, M.D. *Speaker*

University of Illinois At Chicago

Interpreting Meta-Analysis of Antipsychotics

9:10 AM - 9:25 AM

Donald Goff, M.D. *Speaker*

NYU Langone Medical Center

An Update on the Pharmacologic Treatment of Early Psychosis

9:25 AM - 9:40 AM

Jean-Pierre Lindenmayer, M.D. *Speaker*

New York University Grossman School of Medicine, Department of Psychiatry

Update on Strategies for Treatment Resistant Psychosis

9:40 AM - 9:55 AM

Ira Glick, M.D. *Speaker*

Stanford University School of Medicine

Should Antipsychotic Medications for Schizophrenia Be given for a Lifetime? Summary of Four Naturalistic, 6-53 Year Long-Term, Follow-Up Studies of Antipsychotic Treatment for Schizophrenia

9:55 AM - 10:10 AM

Stephen Marder, M.D. *Discussant*

Semel Institute at UCLA

***Ketamine/Esketamine in Psychiatric Disorders across the Lifespan: Therapeutic Potential and the Underlying Biological Mechanisms**

Tue 9 AM - 10:30 AM • Panel • Salon A-E

Madhukar Trivedi, M.D. *Chair*

UT Southwestern Medical Center

9 AM - 9:05 AM

Manish Jha, M.D. *Co-Chair*

University of Texas Southwestern Medical Center

9:05 AM - 9:10 AM

Ibrahim Turkoz, Ph.D. *Speaker*

Janssen R&D, LLC

Irritability in Adults with Treatment-Resistant Depression (TRD) and Treatment Outcomes With Intranasal Esketamine

9:10 AM - 9:25 AM

Sanjay J. Mathew, M.D. *Speaker*

Baylor College of Medicine & Michael E. DeBakey VA Medical Center

A Bayesian Adaptive Randomization Trial to Optimize Intravenous Ketamine Dosing for Late-Life Treatment-Resistant Depression

9:25 AM - 9:40 AM

James Murrough, M.D., Ph.D. *Speaker*

Icahn School of Medicine at Mount Sinai

Role of Stress and Inflammation in the Mechanisms of Depression and Therapeutic Effects of Ketamine

9:40 AM - 9:55 AM

Jennifer Dwyer, M.D., Ph.D. *Speaker*

Boehringer Ingelheim

Ketamine for Pediatric Treatment Resistant Depression and Suicidality: Advances and Challenges

9:55 AM - 10:10 AM

Manish Jha, M.D. *Discussant*

University of Texas Southwestern Medical Center

Break

Tue 10:30 AM - 10:45 AM • Princess East Foyer

Panel Sessions

The panel in Princess Ballroom H: Major Depressive Disorder with Insomnia Symptoms: Characterizing Clinical Burden and Elucidating Biological Mechanisms to Drive Novel Treatment Development is not available for CE credit.

Tue 10:45 AM - 12:15 PM

*Topics in Reproductive Psychiatry

Tue 10:45 AM - 12:15 PM • Panel • Princess Ballroom F

Jennifer Payne, M.D. *Chair*

University of Virginia

10:45 AM - 10:55 AM

Lauren Osborne, M.D. *Speaker*

Johns Hopkins University School of Medicine

Neuroactive Steroids: Mechanism of Action and Investigational Treatment for Depressive Disorders

10:55 AM - 11:15 AM

Jennifer Payne, M.D. *Speaker*

University of Virginia

Neuroactive Steroids in "Reproductive Depression"

11:15 AM - 11:35 AM

Anita H. Clayton, M.D. *Speaker*

University of Virginia

Neuroendocrine Factors Mediate Sexual Dysfunction and Depression

11:35 AM - 11:55 AM

Lauren Osborne, M.D. *Discussant*

Johns Hopkins University School of Medicine

11:55 AM - 12:15 PM

Novel Pharmacotherapies for Post-Traumatic Stress Disorder

Tue 10:45 AM - 12:15 PM • Panel • Princess Ballroom G

George Papakostas, M.D. *Chair*

Massachusetts General Hospital

10:45 AM - 10:50 AM

Ann Rasmusson, M.D. *Co-Chair*

Boston University School of Medicine

10:50 AM - 10:55 AM

Ann Rasmusson, M.D. *Speaker*

Boston University School of Medicine

Role of Gabaergic and Related NMDA Receptor-Active Neurosteroids in Novel Treatment Development for Posttraumatic Stress Disorder (PTSD)

10:55 AM - 11:10 AM

Michael Telch, Ph.D. *Speaker*

The University of Texas At Austin

CBD in the Treatment of Posttraumatic Stress Disorder

11:10 AM - 11:25 AM

Esther Sabban, Ph.D. *Speaker*

New York Medical College

Potential of Intranasal Neuropeptide Y for Prevention and Treatment of PTSD and Associated Neuropsychiatric Disorders

11:25 AM - 11:40 AM

George Papakostas, M.D. *Speaker*

Massachusetts General Hospital

Review of the Current PTSD Pipeline

11:40 AM - 11:55 AM

Maurizio Fava, M.D. *Discussant*

Massachusetts General Hospital

11:55 AM - 12:15 PM

Major Depressive Disorder with Insomnia Symptoms: Characterizing Clinical Burden and Elucidating Biological Mechanisms to Drive Novel Treatment Development

Tue 10:45 AM - 12:15 PM • Panel • Princess Ballroom H

Manish Jha, M.D. *Chair*

University of Texas Southwestern Medical Center

10:45 AM - 10:55 AM

Elizabeth Ballard, Ph.D. *Speaker*

National Institute of Mental Health

Suicide Ideation, Nocturnal Wakefulness and Ketamine

10:55 AM - 11:15 AM

Kruti Joshi, M.P.H. *Speaker*

Janssen Scientific Affairs, LLC

The Impact of Insomnia Symptoms on Clinical and Patient-Centric Outcomes in Major Depressive Disorder: Findings from the National Health and Wellness Survey

11:15 AM - 11:35 AM

Manish Jha, M.D. *Speaker*

University of Texas Southwestern Medical Center

Aberrant Reward Function in Adults with Major Depressive Disorder and Moderate/Severe Insomnia and Association with Acute-Phase Treatment Outcomes

11:35 AM - 11:55 AM

Sanjay J. Mathew, M.D. *Discussant*

Baylor College of Medicine & Michael E. DeBakey VA Medical Center

11:55 AM - 12:15 PM

***Differential Diagnosis of Bipolar II Disorder: What Do We Know and What Does It Mean for an Expert by Experience**

Tue 10:45 AM - 12:15 PM • Panel • Princess Ballroom I

Trisha Suppes, M.D., Ph.D. *Chair*

Stanford University

10:45 AM - 10:50 AM

Holly Swartz, M.D. *Co-Chair*

University of Pittsburgh School of Medicine

10:50 AM - 10:55 AM

Holly Swartz, M.D. *Speaker*

University of Pittsburgh School of Medicine

Bipolar II Disorder and Major Depressive Disorder with Mixed Features: The Same or Different?

10:55 AM - 11:15 AM

Mark Zimmerman, M.D. *Speaker*

Brown University

Diagnosing Bipolar Disorder and Borderline Personality Disorder

11:15 AM - 11:35 AM

sara schley, M.B.A. *Speaker*

B Corp

*Insights from an "Expert by Experience" Who has Lived with Bipolar II for Four Decades

11:35 AM - 11:55 AM

Trisha Suppes, M.D., Ph.D. *Discussant*

Stanford University

11:55 AM - 12:15 PM

Inclusivity Committee Lunch (RSVP Only)

Tue 12:15 PM - 1:45 PM • Princess Ballroom H

Pharmaceutical Pipelines

This session is not available for CE credit.

Co-Chair: Leslie Citrome, New York Medical College

Co-Chair: Carlos Zarate, National Institute of Mental Health

Tue 2 PM - 4 PM • Salon A-E

Brainsonix Technology of Low Intensity Focused Ultrasound Pulse (LIFUP) for Targeted Transcranial Neuromodulation and Delivery of Biological Substances in the Brain

Tue 2 PM - 2:13 PM • Pharmaceutical Pipeline • Salon A-E

Alexander Bystritsky, M.D., Ph.D. *Presenter*

UCLA Semel Institute for Neuroscience and Human Behavior

Auricular Transcutaneous Hi-Frequency E-Mmunotherapy Sequences (ATHENS) for Major Depressive Disorder (MDD) with Peripartum Onset with and without Concomitant Antidepressant Use: A Multicenter, Open-Label Pilot Study

Tue 2:13 PM - 2:26 PM • Pharmaceutical Pipeline • Salon A-E

Kristina Deligiannidis, M.D. *Presenter*

Zucker Hillside Hospital

Emerging Profile of TAAR1 Agonist Ulotaront: Preclinical and Clinical Evidence for an Emerging Pharmacological Class

Tue 2:26 PM - 2:39 PM • Pharmaceutical Pipeline • Salon A-E

Seth C. Hopkins, Ph.D. *Presenter*

Sunovion Pharmaceuticals, Inc.

A Phase 1/2 Trial of GH001, a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation, in Patients with Treatment-Resistant Depression

Tue 2:39 PM - 2:52 PM • Pharmaceutical Pipeline • Salon A-E

Jan Ramaekers, D.Phil. *Presenter*

Maastricht University

COMP360 Psilocybin Therapy in Treatment-Resistant Depression: Results of a Large Randomized Controlled Phase I/II Monotherapy Study and an Exploratory Uncontrolled Adjunctive Therapy Study

Tue 2:52 PM - 3:05 PM • Pharmaceutical Pipeline • Salon A-E

Joyce Tsai, Ph.D. *Presenter*

COMPASS Pathways Ltd.

MK-8189, a Novel PDE10A Inhibitor for the Treatment of Schizophrenia

Tue 3:05 PM - 3:18 PM • Pharmaceutical Pipeline • Salon A-E

Michael Egan, M.D. *Presenter*

Merck & Co., Inc.

Darigabat Reduces Acute Panic and Fear Symptoms Induced by CO2 Inhalation in Healthy Participants

Tue 3:18 PM - 3:31 PM • Pharmaceutical Pipeline • Salon A-E

Rachel Gurrell, Ph.D. *Presenter*

Cerevel Therapeutics, Cambridge

Luvadaxistat, an Investigational D-Amino Acid Oxidase Inhibitor, Was Associated with Signals of Efficacy in Cognitive Impairment Associated with Schizophrenia but Not Negative Symptoms: Results from the Interact Study

Tue 3:31 PM - 3:44 PM • Pharmaceutical Pipeline • Salon A-E

Jaskaran Singh, M.D. *Presenter*

Neurocrine Biosciences

Efficacy and Safety of Zuranolone Co-Initiated with an Antidepressant in Adults with Major Depressive Disorder: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled Coral Study

Tue 3:44 PM - 3:57 PM • Pharmaceutical Pipeline • Salon A-E

Scott Aaronson, M.D. *Presenter*

Sheppard Pratt

Break

Tue 4 PM - 4:15 PM • Princess East Foyer

Individual Research Reports: Brain Health Outcome Studies and Novel Potential Interventions

This session is not available for CE credit.

Chair: Jair Soares

Tue 4:15 PM - 5:30 PM • Princess Ballroom F

Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017)

Tue 4:20 PM - 4:40 PM • Individual Research Report • Princess Ballroom F

Stephen O'Quinn, Pharm.D. *Presenter*

Zynerva Pharmaceuticals

Real-World Clinical Practice among Patients with Bipolar Disorder and Chronic Kidney Disease on Long-Term Lithium Therapy

Tue 4:40 PM - 5 PM • Individual Research Report • Princess Ballroom F

Rakesh Kumar, M.D. *Presenter*

Mayo Clinic

Lower Mortality Due to All-Cause in Patients with Major Depression Treated with ECT Compared to Those Who Did Not: A National United States Study

Tue 5 PM - 5:20 PM • Individual Research Report • Princess Ballroom F

Nagy Youssef, Prof. *Presenter*

The Ohio State University College of Medicine

Individual Research Reports: Depression, Psychosis and Substance Use Disorders (SUD) on the Edge: Impacts on Brain Structures, Social Interactions Impact Outcomes Based on Neighborhoods, and Ketamine for Late-Life TRD to Boot

Chair: Lawrence Cohen

Tue 4:15 PM - 5:30 PM • Princess Ballroom G

Neighborhood Poverty and Hippocampal Volume among Youth at Clinical High Risk for Psychosis: The Moderating Role of Social Engagement

Tue 4:20 PM - 4:35 PM • Individual Research Report • Princess Ballroom G

Benson Ku, M.D. *Presenter*

Emory University School of Medicine

Association between Depression and Change in Nucleus Accumbens Drug Cue-reactivity during Extended-release Naltrexone Treatment for Opioid use Disorder

Tue 4:35 PM - 4:50 PM • Individual Research Report • Princess Ballroom G

Zhenhao Shi, Ph.D. *Presenter*

University of Pennsylvania

Pre-Infusion Neural Complexity Moderates Clinical Response to Intravenous Ketamine Across 7 Days in Patients with Late-Life Treatment Resistant Depression

Tue 4:50 PM - 5:05 PM • Individual Research Report • Princess Ballroom G

Amanda Tamman, M.Sc. *Presenter*

Baylor College of Medicine

Gliovascular Protein Concentrations in the Periphery Show Differential Changes Depending on Clinical Outcome of Transcranial Magnetic Stimulation for Treatment Resistant Depression: New Star of the Show

Tue 5:05 PM - 5:20 PM • Individual Research Report • Princess Ballroom G

Andrew Fukuda, M.D., Ph.D. *Presenter*

Brown University/Butler Hospital

Individual Research Reports: Imaging, Pregnancy Registry and AI: Different Approaches in Mental Health

Chair: Cristina Cusin

Tue 4:15 PM - 5:30 PM • Princess Ballroom H

Using Machine Learning to Predict Depression Care Quality at Community Health Centers during the COVID-19 Pandemic

Tue 4:20 PM - 4:40 PM • Individual Research Report • Princess Ballroom H

Evan Goldstein, Ph.D., M.P.P. *Presenter*

University of Utah School of Medicine

Functional Connectivity between the Orbitofrontal Cortex and Putamen in Opioid use Disorder

Tue 4:40 PM - 5 PM • Individual Research Report • Princess Ballroom H

Mario Montelongo, M.D. *Presenter*

The Menninger Clinic

Individual Research Reports: Tracking Molecular, Physiological, and Behavioral Outcomes in Clinical Studies: Implications for Personalized Therapies and Trial Design

Chair: Brian Mickey

Tue 4:15 PM - 5:30 PM • Princess Ballroom I

Application of a Bayesian Adaptive Randomization Design to Optimize Intravenous Ketamine Dosing for Late-Life Treatment Resistant Depression

Tue 4:20 PM - 4:35 PM • Individual Research Report • Princess Ballroom I

Nicholas Murphy, Ph.D. *Presenter*

Baylor College of Medicine

Using Ecological Momentary Assessment to Identify Potentially Non Adherent Clinical Trials Participants

Tue 4:35 PM - 4:50 PM • Individual Research Report • Princess Ballroom I

Philip Harvey, Ph.D. *Presenter*

University of Miami Miller School of Medicine

Association between the Epigenetic Lifespan Predictor Grimage and History of Suicide Attempt in Bipolar Disorder

Tue 4:50 PM - 5:05 PM • Individual Research Report • Princess Ballroom I

Camila Nayane de Carvalho Lima, Ph.D. *Presenter*

The University of Texas Health Science Center at Houston

Olanzapine/Samidorphan in Young Adults with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who are Early in Their Illness: Results of the Enlighten-Early Study

Tue 5:05 PM - 5:20 PM • Individual Research Report • Princess Ballroom I

John Kane, M.D. *Presenter*

The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

New Investigator Awards Ceremony (Invitation Only)

Tue 6:15 PM - 7:45 PM • Arabian A/B and Patio

WEDNESDAY, JUNE 01

Annual ASCP Fun Run/Walk – All Attendees Welcome

(No Prior Sign Up Necessary)

Wed 6:30 AM - 8 AM • Palomino Conference Center North Drive

Early Career Breakfast (RSVP Only)

Wed 7 AM - 8:20 AM • Princess Ballroom G

NIA Breakfast Roundtable

Wed 7:30 AM - 8:30 AM • Castile 1

Morning Break

Wed 7:30 AM - 9 AM • Princess East Foyer

Speaker Ready Room

Wed 7:30 AM - 6 PM • Bourbon 11

Registration

Wed 7:30 AM - 7 PM • Princess East Foyer Desk

Regulatory Plenary

The Regulatory Plenary for the 2022 ASCP Annual Meeting will be on psychedelics and chaired by Charles Grob, MD.

You will hear perspectives from both the FDA and EMA, followed by a panel Q&A. Participants include:

- Maria Tome, MASc, MD, PhD, FFPM, EMA
- Tiffany Farchione, MD, FDA
- **Dominic Chiapperino, PhD, FDA**
- **Cynthia LaCivita, PharmD, FDA**
- **Georgios Aislaitner, PhD, EMA**

Wed 8:30 AM - 10 AM • Salon A-E

Regulatory Plenary: Psychedelic Drug Development: Perspectives from the FDA and EMA

Wed 8:30 AM - 10 AM • Plenary • Salon A-E

Charles Grob, M.D. *Chair*

Harbor-UCLA Medical Center

8:30 AM - 8:40 AM

Tiffany Farchione, M.D. *Speaker*

US Food and Drug Administration

Psychedelic Drug Development: Regulatory Perspectives from the US Food and Drug Administration and European Medicines Agency

8:40 AM - 8:55 AM

Maria Tome, FRCP, FRCPsych, M.Sc. *Speaker*

European Medicines Agency

Psychedelic Drug Development: Regulatory Perspectives from the US Food and Drug Administration and European Medicines Agency

8:55 AM - 9:10 AM

Dominic Chiapperino, Ph.D. *Speaker*

U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Psychedelic Drug Development: Regulatory Perspectives from the US Food and Drug Administration and European Medicines Agency

9:10 AM - 9:25 AM

Cynthia LaCivita, Pharm.D. *Speaker*

FDA

Psychedelic Drug Development: Regulatory Perspective from the US Food and Drug Administration and European

Medicines Agency

9:25 AM - 9:40 AM

Georgios Aislaitner, Ph.D. *Speaker*

BfArM, Federal Institute for Drugs and Medical Devices

Psychedelic Drugs for the Treatment of Neuropsychiatric Diseases - A European Regulatory View

9:40 AM - 9:55 AM

Break

Wed 10 AM - 10:15 AM • Princess East Foyer

ASCP Awards Ceremony and ASCP Lifetime Awardee Talk

Wed 10:15 AM - 11:15 AM • Salon A-E

Lifetime Awardee Talk

Wed 10:15 AM - 11:15 AM • Plenary • Salon A-E

Madhukar Trivedi, M.D. *Chair*

UT Southwestern Medical Center

10:15 AM - 10:25 AM

Charles Reynolds, M.D. *Speaker*

University of Pittsburgh Medical Center, Western Psychiatric Institute & Clinic

Looking Back, Giving Thanks, and Moving Forward: Reflections on 50 Years as Physician/Scientist/Mentor in Geriatric Psychiatry

10:25 AM - 11:15 AM

Poster Session I with Lunch

Wed 11:15 AM - 1 PM • Palomino Ballroom 4-10

Early Career Networking Tables (Open to all Attendees)

Wed 11:15 AM - 1 PM • Palomino Ballroom 4-10

Program/Steering Committee Meeting (Invitation Only)

Wed 11:30 AM - 12:30 PM • Castile 1

Panel Sessions

The panel in Princess Ballroom F: Racial and Ethnic Disparities in Mental Health and Clinical Trials: What Can Be Done to Enhance Diversity and Eliminate Disparities? is not available for CE credit.

Wed 1 PM - 2:30 PM

Racial and Ethnic Disparities in Mental Health and Clinical Trials: What Can Be Done to Enhance Diversity and Eliminate Disparities?

Wed 1 PM - 2:30 PM • Panel • Princess Ballroom F

Francisco Moreno, M.D. *Chair*

University of Arizona

1 PM - 1:10 PM

Inez Ruiz-White, Ph.D. *Co-Chair*

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Luke Kramer, B.A. *Speaker*

Evolution Research Group

Racial and Ethnic Disparities in Mental Health and Clinical Trials: What Can Be Done to Enhance Diversity and Eliminate Disparities?

1:10 PM - 1:30 PM

John Kraus, M.D., Ph.D. *Speaker*

Otsuka (OPDC)

Racial and Ethnic Disparities in Mental Health and Clinical Trials: What Can Be Done to Enhance Diversity and Eliminate Disparities?

1:30 PM - 1:50 PM

Lionel Philips, M.B.A. *Speaker*

Inside Edge Consulting Group

N/A

1:50 PM - 2:10 PM

Francisco Moreno, M.D. *Discussant*

University of Arizona

2:10 PM - 2:30 PM

Depression, Attentional Bias and Emerging Role of Thyroid Function and Pharmacogenomic Testing in Mood Disorders

Wed 1 PM - 2:30 PM • Panel • Princess Ballroom G

Mark Frye, M.D. *Chair*

Mayo Clinic

1 PM - 1:10 PM

Mark Frye, M.D. *Speaker*

Mayo Clinic

Effects of Liothyronine (T3) in Neuronal Regeneration and Its Implications in Mood Disorders

1:10 PM - 1:25 PM

Michael Gitlin, M.D. *Speaker*

UCLA Medical Center

Revisiting Treatment Implications of the Use of Thyroid Hormones in Mood Disorders

1:25 PM - 1:40 PM

Katherine Burdick, Ph.D. *Speaker*

Brigham and Women's Hospital/Harvard Medical School

The Relationship between Free Triiodothyronine (FT3) and Emotional Processing in Bipolar Disorder

1:40 PM - 1:55 PM

Nicolas Nunez *Speaker*

Mayo Clinic

Deiodinase Variation and Liothyronine Treatment Interaction to Accelerate Ect Response in Major depression: Pilot Data and Implications for Thyroid Pharmacogenomic Testing in Mood Disorders

1:55 PM - 2:10 PM

Randall Espinoza, M.D. *Discussant*

UCLA

2:10 PM - 2:30 PM

Exploring Potential Synergies between Ketamine's Pharmacological Properties and Psychotherapeutic Treatment Approaches

Wed 1 PM - 2:30 PM • Panel • Princess Ballroom H

Gerard Sanacora, M.D., Ph.D. *Chair*

Yale

1 PM - 1:10 PM

Samuel Wilkinson, M.D. *Speaker*

Yale School of Medicine

Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial

1:10 PM - 1:30 PM

Rebecca Price, Ph.D. *Speaker*

University of Pittsburgh

A Brief, Fully Automated Neurocognitive Training Intervention Extends the Antidepressant Effect of a Single Ketamine Infusion

1:30 PM - 1:50 PM

Elias Dakwar, M.D. *Speaker*

College of Physicians & Surgeons Columbia Univ. Chief Division of Epidemiology

Mind, interrupted: Harnessing the Effects of Ketamine in Addiction Treatment

1:50 PM - 2:10 PM

Sanjay J. Mathew, M.D. *Discussant*

Baylor College of Medicine & Michael E. DeBakey VA Medical Center

2:10 PM - 2:30 PM

***Real-World Evidence of Long-Term Ketamine/Esketamine Therapy**

Wed 1 PM - 2:30 PM • Panel • Princess Ballroom I

Balwinder Singh, M.D., M.S. *Chair*

Mayo Clinic

1 PM - 1:10 PM

Jennifer Vande Voort, M.D. *Speaker*

Mayo Clinic

Evidence of IV Ketamine for Treatment-Resistant Unipolar and Bipolar Depression and Observations from Running a Ketamine Clinic

1:10 PM - 1:30 PM

Balwinder Singh, M.D., M.S. *Speaker*

Mayo Clinic

Efficacy and Safety of Ketamine/Esketamine Continuation for Treatment-resistant Depression in Long-term

1:30 PM - 1:50 PM

Simon Kung, M.D. *Speaker*

Mayo Clinic

Long-Term Outcomes and Considerations of Intranasal Esketamine for Treatment Resistant Depression - Is This Really the Miracle Drug?

1:50 PM - 2:10 PM

Patricio Riva-Posse, M.D. *Discussant*

Emory University School of Medicine

2:10 PM - 2:30 PM

Break

Wed 2:30 PM - 2:45 PM • Princess East Foyer

Workshops

The panel in Princess Ballroom F: Mid-Career Workshop: How to Advance Your Career in the Hybrid/Remote Work Environment is not available for CE credit.

Wed 2:45 PM - 4:45 PM •

Mid-Career Workshop: How to Advance Your Career in the Hybrid/Remote Work Environment

Wed 2:45 PM - 4:45 PM • Workshop • Princess Ballroom F

Erika Saunders, M.D. *Chair*

Penn State College of Medicine, Penn State Health

2:45 PM - 2:50 PM

Ross Baker, M.B.A., Ph.D. *Co-Chair*

VistaGen Therapeutics

2:50 PM - 2:55 PM

Carla Canuso, M.D. *Speaker*

Janssen Research & Development

Advancing Your Career in the Hybrid/Remote Work Environment: An Industry Perspective

2:55 PM - 3:15 PM

Kari Nations, Ph.D. *Speaker*

Syneos Health

How to Advance Your Career in the Hybrid/Remote Work Environment

3:15 PM - 3:35 PM

Michael Davis, M.D., Ph.D. *Speaker*

US Food and Drug Administration

How to Advance Your Career in the Hybrid/Remote Work Environment

3:35 PM - 3:55 PM

Controversies in Developing Psychedelic Treatment in Psychiatry

Wed 2:45 PM - 4:45 PM • Workshop • Princess Ballroom G

Trisha Suppes, M.D., Ph.D. *Chair*

Stanford University

2:45 PM - 2:50 PM

Scott Aaronson, M.D. *Co-Chair*

Sheppard Pratt

2:50 PM - 2:55 PM

Scott Aaronson, M.D. *Speaker*

Sheppard Pratt

Improvement from Psychedelic Therapy is Different, How Do We Capture It?

2:55 PM - 3:15 PM

Elizabeth Nielson, Ph.D. *Speaker*

Columbia University & New York State Psychiatric Institute

Psychedelic Therapist Training for Community Practice

3:15 PM - 3:35 PM

Tammy Miller, PsyD *Speaker*

Sheppard Pratt

Psychedelic Assisted Therapy for Depression: Unanswered Questions. Where? When? How Often?

3:35 PM - 3:55 PM

Trisha Suppes, M.D., Ph.D. *Speaker*

Stanford University

Will Psychedelics Change Psychiatric Practice as We Know it?

3:55 PM - 4:15 PM

Mark Rapaport, M.D. *Discussant*

University of Utah Huntsman Mental Health Institute

4:15 PM - 4:45 PM

Early Career Workshop: Psychopharmacology "Prescribers' Workshop" for Trainees and Early Career Clinicians: The Design, Implementation, and Dissemination of a Model Curriculum

Wed 2:45 PM - 4:45 PM • Workshop • Princess Ballroom H

Eileen Kavanagh, M.D. *Chair*

College of Physicians and Surgeons, Columbia University/New York State Psychiatr

2:45 PM - 2:50 PM

David Ross, M.D., Ph.D. *Co-Chair*

University of Alberta, Dept of Psychiatry

2:50 PM - 2:55 PM

Catherine Lowenthal, B.S. *Speaker*

College of Physicians & Surgeons, Columbia University

Invited Workshop: Psychopharmacology "Prescribers' Workshop" for Trainees and Early Career Clinicians: The Design, Implementation, and Dissemination of a Model Curriculum

2:55 PM - 3:25 PM

David Ross, M.D., Ph.D. *Speaker*

University of Alberta, Dept of Psychiatry

Invited Workshop: Psychopharmacology "Prescribers' Workshop" for Trainees and Early Career Clinicians: The Design, Implementation, and Dissemination of a Model Curriculum

3:25 PM - 3:55 PM

Manish Jha, M.D. *Discussant*

University of Texas Southwestern Medical Center

3:55 PM - 4:45 PM

ASCP Business Meeting & Reception (ASCP Members Only)

Wed 5 PM - 6 PM • Princess Ballroom H

ASCP Reception

Wed 6 PM - 7 PM • La Hacienda Plaza & Trellis

THURSDAY, JUNE 02

NIA Breakfast Roundtable

Thu 7:15 AM - 8:15 AM • Castile 1

Morning Break

Thu 7:30 AM - 9 AM • Princess East Foyer

Registration

Thu 7:30 AM - 6 PM • Princess East Foyer Desk

Speaker Ready Room

Thu 7:30 AM - 6 PM • Bourbon 11

Keynote Plenary

The Keynote Plenary for the 2022 ASCP Annual Meeting will be centered on the Annual Meeting's overall theme, *Reassessing Research and Clinical Practice in the Peri-pandemic Era* and chaired by Mark Rapaport, MD.

- The Impact on General Mental and Addiction Care, the Socioeconomic and Political Disruption of Care, and the Change in Care - Roy Perlis, MD
- Neuropsychiatric Impact of the Infection - Scott Beach, MD, FACLP
- Implications for the Design of Future Studies - Eric Lenze, MD

Thu 8:15 AM - 9:45 AM • Salon A-E

Keynote Plenary: Reassessing Research and Clinical Practice in the Peri-pandemic Era

Thu 8:15 AM - 9:45 AM • Plenary • Salon A-E

Mark Rapaport, M.D. *Chair*

University of Utah Huntsman Mental Health Institute

8:15 AM - 8:25 AM

Roy Perlis, M.D. *Speaker*

Massachusetts General Hospital

"This Sense of Being Abandoned": COVID-19 and Mental Health

8:25 AM - 8:45 AM

Eric Lenze, M.D. *Speaker*

Washington University School of Medicine

The Future of Clinical Trials is Remote: The Example of Fluvoxamine during COVID-19

8:45 AM - 9:05 AM

Scott Beach, M.D. *Speaker*

Harvard Medical School, Massachusetts General Hospital

Neuropsychiatric Sequelae of COVID-19

9:05 AM - 9:25 AM

Break

Thu 9:45 AM - 10 AM • Princess East Foyer

Update From Federal and Other Funding Agencies

The Update from Federal and Other Funding Agencies for the 2022 ASCP Annual Meeting will include representatives from NIMH, NIAAA, PCORI, NIDA, SAMSHA, and the VA. The session will be chaired by ASCP's President, Leslie Citrome, MD, MPH.

- Josh Gordon, MD, PhD, NIMH
- George Koob, PhD, NIAAA
- Holly Ramsawh, PhD, PCORI
- Ivan Montoya, MD, NIDA
- Miriam E. Delphin-Rittmon, PhD, SAMHSA
- Jana Drgonova, PhD, VA

Thu 10 AM - 12:30 PM • Salon A-E

Update From Federal and Other Funding Agencies Plenary

Thu 10 AM - 12:30 PM • Plenary • Salon A-E

Leslie Citrome, M.D., M.P.H. *Chair*

New York Medical College

10 AM - 10:10 AM

Josh Gordon, M.D., Ph.D. *Speaker*

National Institute of Mental Health

The Latest in Drug Development from the NIMH

10:10 AM - 10:30 AM

George Koob, Ph.D. *Speaker*

National Institute of Health - NIAAA

Alcohol Use Disorder: Closing the Treatment Gap

10:30 AM - 10:50 AM

Holly Ramsawh, Ph.D. *Speaker*

Patient-Centered Outcomes Research Institute

A 2022 Update on PCORI Research Priorities and Funding Opportunities in Mental Health

10:50 AM - 11:10 AM

Ivan Montoya, M.D., M.P.H. *Speaker*

DHHS/National Institute on Drug Abuse

Update of the Medications Development Program at NIDA

11:10 AM - 11:30 AM

Miriam Delphin-Rittmon, Ph.D. *Speaker*

Substance Abuse and Mental Health Services Administration

An Update from Substance Abuse and Mental Health Services Administration

11:30 AM - 11:50 AM

Jana Drgonova, Ph.D. *Speaker*

Veteran's Administration

VA Office of Research & Development Research on Substance Use Disorders

11:50 AM - 12:10 PM

Poster Session II

Thu 12:30 PM - 2 PM • Palomino Ballroom 4-10

Early Career Networking Tables (Open to all Attendees)

Thu 12:30 PM - 2 PM • Palomino Ballroom 4-10

*Clinical Updates in Psychopharmacology

The Clinical Updates in Psychopharmacology Plenary for the 2022 ASCP Annual Meeting will be chaired by Erika Saunders, MD and will include an update on insomnia, psychosis, and the multimodal approaches to anxiety disorders.

- Insomnia - Andrew Krystal, MD
- Psychosis - Oliver Freudenreich, MD
- Multimodal Approaches to Anxiety Disorders - TBA

Thu 2 PM - 3:30 PM • Salon A-E

Clinical Update in Psychopharmacology

Thu 2 PM - 3:30 PM • Plenary • Salon A-E

Erika Saunders, M.D. *Chair*

Penn State College of Medicine, Penn State Health

2 PM - 2:10 PM

Andrew Krystal, MD, M.D., M.S. *Speaker*

UCSF

Update on Insomnia Pharmacotherapy

2:10 PM - 2:30 PM

Oliver Freudenreich, M.D. *Speaker*

Massachusetts General Hospital

Psychosis Update

2:30 PM - 2:50 PM

Michael E. Thase, M.D. *Speaker*

Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC

Making the Most with What We Have to Offer: Combined and Sequential Therapies for Patients with Difficult to Treat

Mood Disorders

2:50 PM - 3:10 PM

Break

Thu 3:30 PM - 3:45 PM • Princess East Foyer Desk

Panel Sessions

The panel in Princess Ballroom F: Achieving Diversity in Clinical Trials is not available for CE credit.

Thu 3:45 PM - 5:15 PM

Achieving Diversity in Clinical Trials

Thu 3:45 PM - 5:15 PM • Panel • Princess Ballroom F

Shishuka Malhotra, M.D. *Chair*

Neuro Behavioral Clinical Research

3:45 PM - 3:55 PM

Alexandria Wise, Ph.D. *Speaker*

Syneos Health

Practical Implementation of DE&I in Clinical Trials

3:55 PM - 4:15 PM

Charles Wilcox, Ph.D., M.B.A. *Speaker*

Praxis Research Consulting

Diversity, Equity and Inclusion: Globalized Insights for Localized Strategies

4:15 PM - 4:35 PM

Stacey Versavel, Ph.D. *Speaker*

Cerevel Therapeutics

Operationalizing the Enhancement of Diversity in Clinical Trials

4:35 PM - 4:55 PM

Shishuka Malhotra, M.D. *Discussant*

Neuro Behavioral Clinical Research

4:55 PM - 5:15 PM

*Switch versus Augmentation in Treatment-Resistant Depression: Literature and New Findings

Thu 3:45 PM - 5:15 PM • Panel • Princess Ballroom G

George Papakostas, M.D. *Chair*

Massachusetts General Hospital

3:45 PM - 3:55 PM

Maurizio Fava, M.D. *Speaker*

Massachusetts General Hospital

Switching Antidepressants as a Strategy in Resistant Depression

3:55 PM - 4:10 PM

George Papakostas, M.D. *Speaker*

Massachusetts General Hospital

Augmentation versus Switch: Results of the Pcori-Funded Ascertain-Trd Trial

4:10 PM - 4:25 PM

Eric Lenze, M.D. *Speaker*

Washington University School of Medicine

Augmentation Vs. Switching Antidepressants for Treatment Resistant Depression in Older Adults: What Provides the Most Benefits? What is Safest? Results from the Optimum Clinical Trial

4:25 PM - 4:40 PM

Amit Anand, M.D. *Speaker*

MGH Brigham, Harvard Medical School

Comparative Effectiveness of Electroconvulsive Therapy vs. Intravenous Ketamine for Treatment Resistant Depression (ELEKT-D) Trial: Update on Design and Implementation

4:40 PM - 4:55 PM

Michael E. Thase, M.D. *Discussant*

Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC

4:55 PM - 5:15 PM

Digital Measurement and Therapeutics in the Peri-Pandemic Era: Challenges and Opportunities

Thu 3:45 PM - 5:15 PM • Panel • Princess Ballroom H

Timothy Mariano, B.S., M.D., M.Sc., Ph.D., Other *Chair*

Woebot Health; Brown Medical School; Providence VAMC

3:45 PM - 3:55 PM

Cynthia Epperson, M.D. *Speaker*

University of Colorado Anschutz Medical Campus

No Looking Back: Tech-Enabling the Practice of Psychiatry

3:55 PM - 4:10 PM

Georgia Mitsi, Ph.D. *Speaker*

Biogen

Digital Biomarkers and Their Application in Everyday Mental Health Care

4:10 PM - 4:25 PM

Ellen Frank, Ph.D. *Speaker*

University of Pittsburgh School of Medicine

Developing, Testing, and Taking a Digital Intervention for Depression to FDA Indication: Challenges and Opportunities

4:25 PM - 4:40 PM

Alison Darcy, Ph.D. *Speaker*

Woebot Health

Software as a Medical Device for Treatment of Mental Health Conditions: Promise and Challenge

4:40 PM - 4:55 PM

Justin Baker, M.D., Ph.D. *Discussant*

Harvard Medical School McLean Hospital

4:55 PM - 5:05 PM

An ASCP/AFSP Panel: Using Technology for Suicide Prevention

Thu 3:45 PM - 5:15 PM • Panel • Salon A-E

Jill Harkavy-Friedman, Ph.D. *Chair*

American Foundation for Suicide Prevention

3:45 PM - 3:50 PM

Madhukar Trivedi, M.D. *Co-Chair*

UT Southwestern Medical Center

3:50 PM - 3:55 PM

Matthew Nock, Ph.D. *Speaker*

Harvard University

Using New Technology to Improve the Prediction and Prevention of Suicidal Behavior

3:55 PM - 4:15 PM

Scott Langenecker, Ph.D. *Speaker*

University of Utah

Challenges and Opportunities for Text-Based Crisis Response - Lessons Learned in 2020 with SafeUT

4:15 PM - 4:35 PM

Jill Harkavy-Friedman, Ph.D. *Speaker*

American Foundation for Suicide Prevention

Technology as a Tool and Outcome in Clinical Trials

4:35 PM - 4:55 PM

Madhukar Trivedi, M.D. *Discussant*

UT Southwestern Medical Center

4:55 PM - 5:15 PM

FRIDAY, JUNE 03

Morning Break

Fri 7:30 AM - 9 AM • Princess East Foyer

Speaker Ready Room

Fri 7:30 AM - 10:30 AM • Bourbon 11

Registration

Fri 7:30 AM - 12 PM • Princess East Foyer Desk

Panel Sessions

The panel in Princess Ballroom G: Challenges and Opportunities in the Use of Real-World Evidence to Advance Treatment Development in Behavioral Health is not available for CE credit.

Fri 8:30 AM - 10 AM

*Augmenting Vs. Switching Antidepressant for Treatment Resistant Depression in Older Adults: Results from the Optimum Study

Fri 8:30 AM - 10 AM • Panel • Princess Ballroom F

Helen Lavretsky, M.D. *Chair*

David Geffen School of Medicine at UCLA

8:30 AM - 8:40 AM

Jordan Karp, M.D. *Speaker*

University of Arizona

Pragmatism, Context, and Lessons Learned: Planning for Impactful Dissemination

8:40 AM - 9 AM

Eric Lenze, M.D. *Speaker*

Washington University School of Medicine

What Treatment Choices Are effective? Safe? Futile? Results from the Optimum Study

9 AM - 9:20 AM

Helen Lavretsky, M.D. *Speaker*

David Geffen School of Medicine at UCLA

Optimizing Outcomes of Treatment-Resistant Depression (TRD) in Older Adults (OPTIMUM): Effects on Psychological Well-Being

9:20 AM - 9:40 AM

Charles Reynolds, M.D. *Discussant*

University of Pittsburgh Medical Center, Western Psychiatric Institute & Clinic

9:40 AM - 10 AM

*Challenges and Opportunities in the Use of Real-World Evidence to Advance Treatment Development in Behavioral Health

Fri 8:30 AM - 10 AM • Panel • Princess Ballroom G

Scott Kollins, Ph.D. *Chair*

Holmusk

8:30 AM - 8:40 AM

Luca Pani, M.D. *Speaker*

University of Miami

Real-World Evidence Data in Pharmaceutical Products R&D from Registration to Reimbursement: Challenges and Opportunities

8:40 AM - 9 AM

Shuvayu Sen, Ph.D. *Speaker*

Otsuka Pharmaceutical Companies

Industry Perspective on RWE for Behavioral Health

9 AM - 9:20 AM

Durga Borkar, M.D. *Speaker*

Duke University Eye Center

Using Real World Data to Generate High Quality Real World Evidence: Lessons Learned from Ophthalmology

9:20 AM - 9:40 AM

Tiffany Farchione, M.D. *Discussant*

US Food and Drug Administration

9:40 AM - 10 AM

Neurophysiological Biomarkers in the Context of Early Phase Clinical Trials for Major Depressive Disorder

Fri 8:30 AM - 10 AM • Panel • Salon A-E

Nicholas Murphy, Ph.D. *Chair*

Baylor College of Medicine

8:30 AM - 8:35 AM

Sanjay J. Mathew, M.D. *Co-Chair*

Baylor College of Medicine & Michael E. DeBakey VA Medical Center

8:35 AM - 8:40 AM

Nicholas Murphy, Ph.D. *Speaker*

Baylor College of Medicine

Applying Neurophysiological Biomarkers to Clinical Trials of NMDA Receptor Modulation for the Treatment of Mood and Trauma Disorders

8:40 AM - 9 AM

Daphne Voineskos, FRCP(C) *Speaker*

University of Toronto

TMS-EEG Indices as High Potential Predictive Markers of Brain Stimulation Response in Major Depressive Disorder

9 AM - 9:20 AM

Jessica Gilbert, Ph.D. *Speaker*

National Institute of Mental Health

Electrophysiological Biomarkers of Ketamine Response in Treatment-Resistant Major Depression

9:20 AM - 9:40 AM

Carlos Zarate, M.D. *Discussant*

National Institute of Mental Health

9:40 AM - 10 AM

Break

Fri 10 AM - 10:15 AM • Princess East Foyer

Regulatory Wrap-Up Plenary

Fri 10:15 AM - 11:45 AM • Salon A-E

Regulatory Wrap-Up

Fri 10:15 AM - 11:45 AM • Plenary • Salon A-E

Trisha Suppes, M.D., Ph.D. *Chair*

Stanford University

10:15 AM - 10:25 AM

Maria Tome, FRCP, FRCPsych, M.Sc. *Speaker*

European Medicines Agency

Regulatory Wrap-Up

10:25 AM - 10:45 AM

Tiffany Farchione, M.D. *Speaker*

US Food and Drug Administration

Regulatory Wrap-Up

10:45 AM - 11:05 AM

Bernard Fischer, M.D. *Speaker*

U.S. Food and Drug Administration

Regulatory Wrap-Up

11:05 AM - 11:25 AM

Marion Haberkamp, M.D. *Speaker*

Federal Institute of Drugs and Medical Devices, BfArM, Germany

Regulatory Wrap-Up

11:25 AM - 11:45 AM

PRE-RECORDED SESSIONS

Pre-Recorded Sessions

Biomarkers of Response to Ketamine in Treatment-Resistant Depression

• Panel

Mark Frye, M.D. *Chair*

Mayo Clinic

Sagar Parikh, FRCPC, M.D. *Speaker*

University of Michigan, Ann Arbor

A Single-Arm, Open-Label Study of Biomarkers of Remission with IV Ketamine for Non-Psychotic Unipolar or Bipolar Treatment-Refractory Depression: Clinical Outcomes

Rima Kaddurah-Daouk, Ph.D. *Speaker*

Duke University School of Medicine

Metabolomics Informs about Rapid Mechanism of Action of Ketamine and Varied Response to Treatment

Balwinder Singh, M.D., M.S. *Speaker*

Mayo Clinic

Central Biomarkers of Ketamine Response

Mark Frye, M.D. *Discussant*

Mayo Clinic

***Metabolic Health in Severe Mental Illness: Novel Intervention Strategies toward Reducing the Mortality Gap**

• Panel

Margaret Hahn, M.D., Ph.D., FRCPC *Chair*

Centre for Addiction and Mental Health

Cynthia Calkin, FRCP(C), M.D. *Co-Chair*

Dalhousie University Faculty of Medicine

Dan Siskind, M.D. *Speaker*

The University of Queensland

Preventing Antipsychotic Induced Weight Gain – An RCT of Metformin to Ameliorate Weight Gain with Clozapine

Mahavir Agarwal, M.D., Ph.D., Other *Speaker*

Centre for Addiction and Mental Health (CAMH), Canada

Metformin for the Prevention of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis, and a Retrospective Chart Review

Cynthia Calkin, FRCP(C), M.D. *Speaker*

Dalhousie University Faculty of Medicine

Treating insulin Resistance to Improve Outcomes in Bipolar Disorder (TRIO-BD) Study Results Suggest Underlying Mechanism of Treatment Resistant Bipolar Depression

Benjamin Perry, M.D., Ph.D. *Speaker*

University of Cambridge

International External Validation and Revision in Two Countries of the Psymetric Cardiometabolic Risk Prediction Algorithm for Young People with Psychosis

Christoph Correll, M.D. *Discussant*

The Zucker Hillside Hospital